SIGA Technologies Appoints New Chief Medical Officer
Ticker: SIGA · Form: 8-K · Filed: Sep 20, 2024 · CIK: 1010086
| Field | Detail |
|---|---|
| Company | Siga Technologies Inc (SIGA) |
| Form Type | 8-K |
| Filed Date | Sep 20, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel
TL;DR
SIGA brings back Dr. Smith as CMO, effective Sept 19th.
AI Summary
SIGA Technologies, Inc. announced on September 20, 2024, that Dr. Dennis H. Smith will be appointed as Chief Medical Officer, effective September 19, 2024. Dr. Smith previously served as the company's Chief Medical Officer from 2015 to 2022 and rejoins SIGA after a period of absence. His appointment is part of the company's ongoing efforts in its pharmaceutical preparations sector.
Why It Matters
The appointment of a Chief Medical Officer is crucial for a pharmaceutical company like SIGA Technologies, as this role oversees clinical development and medical strategy, directly impacting the company's product pipeline and regulatory approvals.
Risk Assessment
Risk Level: low — This filing is a routine personnel announcement regarding a key executive, with no immediate financial or operational risks indicated.
Key Players & Entities
- SIGA Technologies, Inc. (company) — Registrant
- Dr. Dennis H. Smith (person) — Appointed Chief Medical Officer
- September 19, 2024 (date) — Effective date of appointment
- September 20, 2024 (date) — Date of report
- 2015 to 2022 (date) — Previous tenure as CMO
FAQ
What is the effective date of Dr. Dennis H. Smith's appointment as Chief Medical Officer?
Dr. Dennis H. Smith's appointment as Chief Medical Officer is effective September 19, 2024.
Has Dr. Dennis H. Smith held this position before at SIGA Technologies?
Yes, Dr. Smith previously served as the Chief Medical Officer of SIGA Technologies from 2015 to 2022.
What is the primary business of SIGA Technologies, Inc. according to the filing?
SIGA Technologies, Inc. is primarily involved in Pharmaceutical Preparations, with SIC code 2834.
What is the filing date of this 8-K report?
This 8-K report was filed as of date September 20, 2024.
What is the principal executive office address for SIGA Technologies, Inc.?
The principal executive offices are located at 31 East 62nd Street, New York, New York 10065.
Filing Stats: 418 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2024-09-20 16:07:46
Filing Documents
- ef20036098_8k.htm (8-K) — 24KB
- 0001140361-24-041564.txt ( ) — 154KB
- siga-20240919.xsd (EX-101.SCH) — 4KB
- siga-20240919_lab.xml (EX-101.LAB) — 21KB
- siga-20240919_pre.xml (EX-101.PRE) — 16KB
- ef20036098_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 19, 2024, Dr. Jay K. Varma began an indefinite leave of absence from his positions as Executive Vice President and Chief Medical Officer of SIGA Technologies, Inc. (the "Company") and as a member of the Board of Directors of the Company.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SIGA TECHNOLOGIES, INC. By: /s/ Daniel J. Luckshire Name: Daniel J. Luckshire Title: Chief Financial Officer Date: September 20 , 2024